These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 18997301

  • 1. Antioxidants in central nervous system diseases: preclinical promise and translational challenges.
    Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K.
    J Alzheimers Dis; 2008 Nov; 15(3):473-93. PubMed ID: 18997301
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Benefits of curcumin in brain disorders.
    Bhat A, Mahalakshmi AM, Ray B, Tuladhar S, Hediyal TA, Manthiannem E, Padamati J, Chandra R, Chidambaram SB, Sakharkar MK.
    Biofactors; 2019 Sep; 45(5):666-689. PubMed ID: 31185140
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biological metals and metal-targeting compounds in major neurodegenerative diseases.
    Barnham KJ, Bush AI.
    Chem Soc Rev; 2014 Oct 07; 43(19):6727-49. PubMed ID: 25099276
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S, Pérez-Neri I, Ríos C, Tristán-López L, Rivera-Espinosa L, Montes S.
    Chem Biol Interact; 2010 Jul 30; 186(2):184-99. PubMed ID: 20399203
    [Abstract] [Full Text] [Related]

  • 15. Mitochondria and neurodegeneration.
    Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M.
    Biosci Rep; 2007 Jun 30; 27(1-3):87-104. PubMed ID: 17486441
    [Abstract] [Full Text] [Related]

  • 16. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.
    Choonara YE, Pillay V, Du Toit LC, Modi G, Naidoo D, Ndesendo VMK, Sibambo SR.
    Int J Mol Sci; 2009 Jun 03; 10(6):2510-2557. PubMed ID: 19582217
    [Abstract] [Full Text] [Related]

  • 17. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
    Bansal R, Singh R.
    Med Res Rev; 2018 Jul 03; 38(4):1126-1158. PubMed ID: 28697282
    [Abstract] [Full Text] [Related]

  • 18. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders.
    Di Domenico F, Tramutola A, Butterfield DA.
    Free Radic Biol Med; 2017 Oct 03; 111():253-261. PubMed ID: 27789292
    [Abstract] [Full Text] [Related]

  • 19. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders.
    van Muiswinkel FL, Kuiperij HB.
    Curr Drug Targets CNS Neurol Disord; 2005 Jun 03; 4(3):267-81. PubMed ID: 15975029
    [Abstract] [Full Text] [Related]

  • 20. Mitochondria: a therapeutic target in neurodegeneration.
    Moreira PI, Zhu X, Wang X, Lee HG, Nunomura A, Petersen RB, Perry G, Smith MA.
    Biochim Biophys Acta; 2010 Jan 03; 1802(1):212-20. PubMed ID: 19853657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.